The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma

R Donne, A Lujambio - Hepatology, 2023 - journals.lww.com
The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy

X Gao, Y Mi, NA Guo, H Xu, L Xu, X Gou… - Frontiers in …, 2017 - frontiersin.org
Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD3+ CD56+
natural killer T cells, which can be easily expanded in vitro from peripheral blood …

Extra-large pore mesoporous silica nanoparticles enabling co-delivery of high amounts of protein antigen and toll-like receptor 9 agonist for enhanced cancer vaccine …

BG Cha, JH Jeong, J Kim - ACS central science, 2018 - ACS Publications
Cancer vaccine aims to invoke antitumor adaptive immune responses to detect and
eliminate tumors. However, the current dendritic cells (DCs)-based cancer vaccines have …

[HTML][HTML] Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma

M Shi, B Zhang, ZR Tang, ZY Lei, HF Wang… - World journal of …, 2004 - ncbi.nlm.nih.gov
AIM: To investigate the influence of autologous cytokine-induced killer (CIK) cells on the
phenotypes of CIK effector cells, peripheral T lymphocyte subsets and dendritic cell subsets …

Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity

A Pievani, G Borleri, D Pende, L Moretta… - Blood, The Journal …, 2011 - ashpublications.org
Abstract CD3+ CD56+ cytokine-induced killer (CIK) cells display a potent cytolytic activity.
The adhesion molecule lymphocyte function-associated antigen-1 plays a crucial role in …

Interleukin-2 therapy of cancer-clinical perspectives

J Majidpoor, K Mortezaee - International immunopharmacology, 2021 - Elsevier
Abstract Interleukin (IL)-2 is a pleiotropic cytokine that displays opposing activities on
immune system acting either in favor of or against cancer progression. Advanced/metastatic …

Targeting PD-1 and Tim-3 pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic/tumor vaccines

J Liu, S Zhang, Y Hu, Z Yang, J Li, X Liu… - Journal of …, 2016 - journals.lww.com
The paradoxical coexistence of spontaneous tumor antigen-specific immune response with
progressive disease in cancer patients need to dissect the molecular pathways involved in …

Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients

L Yang, B Ren, H Li, J Yu, S Cao, X Hao… - Cancer immunology …, 2013 - Springer
Cytokine-induced killer (CIK) cells show cytolytic activity against tumor. The purpose of this
study was to evaluate the antitumor effect of dendritic cell (DC)-activated CIK cells in vitro …

Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia

YC Linn, KM Hui - Leukemia & lymphoma, 2003 - Taylor & Francis
Cytokine-induced killer (CIK) cells are a unique population of cytotoxic T lymphocytes (CTL)
with the characteristic CD3+ CD56+ phenotype. These cells have demonstrated higher …

Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery

H Li, C Wang, J Yu, S Cao, F Wei, W Zhang, Y Han… - …, 2009 - Taylor & Francis
Background aims Cytokine-induced killer (CIK) cells have shown cytolytic activity against
several tumor cells in vitro and in animal tumor models. Furthermore, CIK cells activated by …